Abstract
Background The paucity of data on the epidemiology of bloodstream infection (BSI) in low and middle-income countries (LMICs) limits its effective prevention and management. This review sought to determine the prevalence, bacteriological and antimicrobial resistance profiles of bacteria implicated in BSI in Cameroon.
Methods PubMed and Google Scholar databases were searched to identify relevant articles, which were screened according to the PRISMA guidelines. The data were analysed using comprehensive meta-analysis software. The I2 was used to evaluate heterogeneity between studies, Begg’s and Egger’s regression tests were used to evaluate publication bias, and random effects analysis was used to calculate the pooled prevalence.
Results A total of 4223 blood cultures were obtained from the 10 included studies. The overall pooled prevalence of bacterial BSI was 26.31% (95% CI= 17.01%–38.35%). Escherichia coli (23.09%; 95% CI= 9.21%–47.05%), Klebsiella spp. (22.95%; 95% CI= 13.09%–37.07%), and Staphylococcus aureus (16.09%; 95% CI= 8.11%–29.43%) were the most common bacteria species. E. coli and Klebsiella spp. displayed the highest resistance to amoxicillin (82.65%; 95% CI= 63.25%–92.95% vs 86.42%; 95% CI= 55.90%–96.97%), amoxicillin + clavulanic acid (71.74%; 43.96–89.15% vs 73.06%; 95% CI= 38.70%–92.09%) and cotrimoxazole (76.22%; 95% CI= 51.33%–90.79% vs 65.81%; 95% CI= 45.08–81.86%). However, meropenem (26.73%; 95% CI= 20.76%–33.68%) and fosfomycin (14.85%; 95% CI= 9.07%–23.37%) were the least resistant in E. coli and Klebsiella spp., respectively. Staphylococcus aureus strains exhibited highest resistance to penicillin (84.37%; 95% CI= 68.13%–93.16%), erythromycin (44.80%; 95% CI= 33.37%–56.79%) and oxacillin (37.35%; 95% CI= 8.76%–78.74%) and lowest resistance to rifampicin (2.94%; 95% CI= 0.59%–13.39%), fusidic acid (6.73%; 95% CI= 2.55%–16.62%) and vancomycin (13.18%; 95% CI= 2.26%–49.86%).
Conclusion This study reports a high prevalence of bacterial BSIs in Cameroon and the high resistance of these bacteria to common antibiotics. There is a pressing need to conduct BSI surveillance studies in all regions of Cameroon to generate data for evidence-based measures regarding BSI prevention and management.
Prospero registration number CRD42023482760
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We performed another analysis without subgrouping our study population because we noticed an overlap between the two subgroups and we reorganised our results accordingly; also, we added additional files to support our analysis and study.
Data Availability
All data produced in the present work are contained in the manuscript
List of abbreviations
- AMR
- Antimicrobial Resistance
- BSI
- Bloodstream Infections
